Divergent Clinical and Immunologic Outcomes Based on STK11 Co-mutation Status in Resectable KRAS-Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade
⚠︎Low quality — median 91 genes per cell. Datasets below 100 genes/cell may not produce meaningful analysis results.